About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Sftpc+
wild type
MGI:2434380
Summary 5 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
\Mettm1Sst/\Mettm1Sst
\Sftpctm1(cre/ERT2,rtTA)Hap/\Sftpc+
involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N MGI:6197801
cn2
\Krastm4Tyj/\Kras+
\Sftpctm1.1(cre/ERT2)Ptch/\Sftpc+
\Trp53tm1Brn/\Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB MGI:5486065
cn3
\Krastm4Tyj/\Kras+
\Sftpctm1.1(cre/ERT2)Ptch/\Sftpc+
involves: 129P2/OlaHsd * C57BL/6 * FVB MGI:5486056
cn4
\Krastm4Tyj/\Kras+
\Sftpctm1(cre/ERT2)Blh/\Sftpc+
\Trp53tm5Tyj/\Trp53+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 MGI:5317171
cn5
\Ptpratm1c(EUCOMM)Hmgu/\Ptpratm1c(EUCOMM)Hmgu
\Sftpctm1(cre/ERT2)Blh/\Sftpc+
involves: 129S6/SvEvTac * C57BL/6N MGI:6690444


Genotype
MGI:6197801
cn1
Allelic
Composition
\Mettm1Sst/\Mettm1Sst
\Sftpctm1(cre/ERT2,rtTA)Hap/\Sftpc+
Genetic
Background
involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mettm1Sst mutation (1 available); any Met mutation (81 available)
Sftpctm1(cre/ERT2,rtTA)Hap mutation (0 available); any Sftpc mutation (22 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• tamoxifen-treated mice show reduced density of alveoli
• alveoli are enlarged in tamoxifen-treated mice
• adult mice treated with tamoxifen exhibit enlargement of alveolar airspace and loss of alveolar density, indicating emphysematous changes




Genotype
MGI:5486065
cn2
Allelic
Composition
\Krastm4Tyj/\Kras+
\Sftpctm1.1(cre/ERT2)Ptch/\Sftpc+
\Trp53tm1Brn/\Trp53tm1Brn
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm4Tyj mutation (12 available); any Kras mutation (88 available)
Sftpctm1.1(cre/ERT2)Ptch mutation (0 available); any Sftpc mutation (22 available)
Trp53tm1Brn mutation (21 available); any Trp53 mutation (249 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• many mice do not survive to 13 weeks after tamoxifen treatment due to high tumor burden
• mice display leaky cre expression without tamoxifen treatment and survive a few months longer than tamoxifen-treated animals

neoplasm
• after tamoxifen treatment, mice show a more severe phenotype than animals with wild-type Trp53 (greater tumor size, tumor growth and tumor grade); by 3-4 weeks after tamoxifen treatment, several small adenomas of papillary nature are observed in alveoli
• at 10 weeks after tamoxifen injection, many alveoli have large tumors; tumors exhibit enlarged pleomorphic nuclei, aberrant mitosis; tumor giant cells are present
• mice surviving to 13 weeks after tamoxifen treatment have adenocarcinomas in the alveoli of the lungs
• without tamoxifen treatment, mice develop invasive lung adenocarcinomas localized to the alveoli
• bronchioalveolar duct junctions (BADJs) appear normal ( in mice with or without tamoxifen treatment)

respiratory system
• after tamoxifen treatment, mice show a more severe phenotype than animals with wild-type Trp53 (greater tumor size, tumor growth and tumor grade); by 3-4 weeks after tamoxifen treatment, several small adenomas of papillary nature are observed in alveoli
• at 10 weeks after tamoxifen injection, many alveoli have large tumors; tumors exhibit enlarged pleomorphic nuclei, aberrant mitosis; tumor giant cells are present
• mice surviving to 13 weeks after tamoxifen treatment have adenocarcinomas in the alveoli of the lungs
• without tamoxifen treatment, mice develop invasive lung adenocarcinomas localized to the alveoli
• bronchioalveolar duct junctions (BADJs) appear normal ( in mice with or without tamoxifen treatment)
• 8 days after tamoxifen treatment, extensive type II cell proliferation is observed compared to wild-type; however, proliferating bronchioalveolar stem cells (BASCs) are rarely observed (at 8 days, 3, 6, 10 and 13 weeks after tamoxifen treatment)
• tumor cells express type II cell markers and are highly proliferative, even without tamoxifen treatment




Genotype
MGI:5486056
cn3
Allelic
Composition
\Krastm4Tyj/\Kras+
\Sftpctm1.1(cre/ERT2)Ptch/\Sftpc+
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6 * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm4Tyj mutation (12 available); any Kras mutation (88 available)
Sftpctm1.1(cre/ERT2)Ptch mutation (0 available); any Sftpc mutation (22 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• by 18 weeks after tamoxifen treatment, numerous adenomas develop in alveoli; small numbers of cells with features of malignant transformation are observed in some lung sections
• tumors are usually found in proximity to the airways, bronchioalveolar duct junctions (BADJs), or surface of the lung, but lesions are not found in the BADJs
• tumor cells are highly proliferative
• airways and BADJs retain normal architecture

respiratory system
• by 18 weeks after tamoxifen treatment, numerous adenomas develop in alveoli; small numbers of cells with features of malignant transformation are observed in some lung sections
• tumors are usually found in proximity to the airways, bronchioalveolar duct junctions (BADJs), or surface of the lung, but lesions are not found in the BADJs
• tumor cells are highly proliferative
• airways and BADJs retain normal architecture




Genotype
MGI:5317171
cn4
Allelic
Composition
\Krastm4Tyj/\Kras+
\Sftpctm1(cre/ERT2)Blh/\Sftpc+
\Trp53tm5Tyj/\Trp53+
Genetic
Background
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm4Tyj mutation (12 available); any Kras mutation (88 available)
Sftpctm1(cre/ERT2)Blh mutation (1 available); any Sftpc mutation (22 available)
Trp53tm5Tyj mutation (1 available); any Trp53 mutation (249 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice die 14 weeks or less after tamoxifen administration

neoplasm
• at 6-8 weeks of age, animals administered 1dose or 4 doses of tamoxifen develop widespread adenomas in the alveoli by 14 weeks of age, but the bronchoalveolar duct junction remains tumor-free
• at 6-8 weeks of age, animals administered 1dose or 4 doses of tamoxifen develop widespread adenocarcinomas in the alveoli by 14 weeks of age

respiratory system
• at 6-8 weeks of age, animals administered 1dose or 4 doses of tamoxifen develop widespread adenomas in the alveoli by 14 weeks of age, but the bronchoalveolar duct junction remains tumor-free
• at 2 weeks after tamoxifen treatement, brochioalveolar duct junctions (BADJ) appear normal, but small adenomas occur in the alveoli; these progress to adenocarcinoma but the BADJ remain histologically normal




Genotype
MGI:6690444
cn5
Allelic
Composition
\Ptpratm1c(EUCOMM)Hmgu/\Ptpratm1c(EUCOMM)Hmgu
\Sftpctm1(cre/ERT2)Blh/\Sftpc+
Genetic
Background
involves: 129S6/SvEvTac * C57BL/6N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptpratm1c(EUCOMM)Hmgu mutation (0 available); any Ptpra mutation (44 available)
Sftpctm1(cre/ERT2)Blh mutation (1 available); any Sftpc mutation (22 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
N
• bleomycin, tamoxifen-treated mice develop fibrosis and lung collagen content as in control mice





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
03/25/2025
MGI 6.24
The Jackson Laboratory